Device based treatment of heart failure

Postgraduate Medical Journal

Volumn 81, Issue 955, 2005, Pages 286-291

  Patwala, A Y ^a   Wright, D J ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENCAINIDE; EPLERENONE; FLECAINIDE; MORACIZINE; PLACEBO; SPIRONOLACTONE;

AGING; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DEVICE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART RESYNCHRONIZATION DEVICE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; OXYGEN CONSUMPTION; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUDDEN DEATH; SYNCOPE; THORAX RADIOGRAPHY;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS; PACEMAKER, ARTIFICIAL; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 18844365136     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.026716     Document Type: Review

References (89)

1. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the echocardiographic heart of England screening study: a population based study. Lancet 2001;358:439-44.
2. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J Suppl 2003;5(suppl 1):13-13.
3. Bonneux L, Barendregt JJ, Meeter K, et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994;84:20-8.
4. Cleland JGF, Gemmell I, Khand A, et al. Is the prognosis of heart failure improving? Eur J Heart Failure 1999;1:229-41.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
6. Farwell D, Patel NR, Hall A, et al. How many people with heart failure are appropriate for biventricular resynchronization? Eur Heart J 2000;21:1246-50.
7. Stellbrink C, Auricchio A, Diem B, et al. Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. Am J Cardiol 1999;83:143-50D.
8. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997;30:1589-97.
9. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
10. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult (1st of 2 parts). N Engl J Med 1982;307:1051-8.
11. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
12. National Institute for Clinical Evidence. Management af chronic heart failure in adults in primary and secondary care. http://www.nice.org.uk/pdf/ CG5NICEguideline.pdf.
13. Bohm M, Kilter H, Kindermann M. Mechanisms contributing to the progression of left ventricular dysfunction to end-stage heart failure. Eur Heart J Suppl, 2003;5(suppl 1) 14-21.
14. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
15. van Kats JP, Danser AHJ, van Meegen JR, et al. Angiotensin production by the heart. Circulation 1998;98:73-81.
16. Jong P, Demers C, McKelvie RS, et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463-70.
17. CIBIS Investigators and Committees. A randomised trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994;90:1765-73.
18. Packer M, Bristow M, Cohn J, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
19. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
20. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
21. Pitt B, Remme W, Zannad F, et al. Eplerenone: a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
22. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
23. Philbin EF, Andreou C, Rocco TA, et al. Patterns of angiotensin- converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
24. Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998;158:1074-80.
25. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice. J Am Coll Cardiol 1996;28:1323-7.
26. Kjekshus J, Swedberg K. Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988;62:67-72A.
27. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-12.
28. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-18.
29. The CONSENSUS trial group. Effect of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
30. Bradley DJ. Combining resynchronization and defibrillation therapies for heart failure. JAMA 2003;289:2719-21.
31. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 1986;314:1547-52.
32. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-10.
33. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death. Circulation 2000;102:611-16.
34. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991; 324:781-8.
35. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent Moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
36. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survival (BASIS). J Am Coll Cardiol 1990;16:1711-18.
37. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
38. Garguichevich JJ, Ramos JL, Gambarte A, et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine pilot study of sudden death and amiodarone (EPAMSA). Am Heart J 1995;130:494-500.
39. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study. Eur Heart J 2000;21:198-205.
40. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
41. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
42. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cordial 1992;20:1056-62.
43. Navarro-Lopez F, Cosin J, Marrugat J, et al. Comparison of the effect of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol 1993;72:1243-8.
44. Hackings BE, George T, Mahrous F, et al. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. Am J Cardiol 1987;60:967-70.
45. Cairns JA, Connolly SJ, Gent M, et al. Post myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian amiodarone myocardial infarction arrhythmia trial pilot study. Circulation 1991;84:550-7.
46. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
47. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122:1016-21.
48. Hamer AW, Arkles B, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989;14:1768-74.
49. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 1999;84:90-3R.
50. The AVID investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
51. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS). Circulation 2000;101:1297-302.
52. Kuck KH, Cappato R, Siebels J, et al. Randomised comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. Circulation 2000;102:748-54.
53. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21:2071-8.
54. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
55. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90.
56. Klein HU, Reek S. The MUSTT study: evaluating, testing and treatment. J Interven Card Electophysiol 2000;4:45-50.
57. Moss AJ, Daubert J, Zareba W. MADIT-II: clinical implications. Cardiol Electrophysiol Rev 2002;6:463-5.
58. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
59. Moss AJ. Findings from the MADIT-II substudies. Eur Heart J Suppl 2003;5(suppl 1):134-8.
60. Bardy GH. SCD-HeFT: the sudden cardiac death in heart failure trial. http:// www.acc04online.acc.org.
61. Dougherty CM. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung 1995;24:281-91.
62. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable defibrillator shocks by treatment with Sotalol. N Engl J Med 1999;340:1855-62.
63. The CASCADE investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. Am J Cardiol 1993;72:280-7.
64. Kass DA. Ventricular remodelling: chamber dyssynchrony and effects of cardiac resynchronization. Eur Heart J Suppl 2003;5(suppl 1):154-63.
65. Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000;102:3053-9.
66. Hare JM. Cardiac resynchronization therapy for heart failure. N Engl J Med 2002;346:1902-05.
67. Gottipaty VK, Krelis SP, Lu F, et al. The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. (Abstract), J Am Coll Cardiol 1999;33:847-4.
68. Cazeau S, Ritter P, Lazarus A, et al. Multisite pacing for end-stage heart failure: early experience. Pacing Clin Electrophysiol 1996; 19:1748-57.
69. Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999;99:1567-73.
70. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure. Circulation 1997;96:3273-7.
71. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-3001.
72. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002;39:194-201.
73. Auricchio A, Stellbrink C, Sack S, et al. Long term clinical effects of hemodynamically optimised cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026-33.
74. Cazeau S, Leclercq C, Lavergne T, et al. Effect of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
75. Gras D, Leclercq C, Tang ASL, et al. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. Eur J Heart Fail 2002;4:311-20.
76. Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular pre-excitation improves mechanoenergetics of patients with dilated cardiomyopathy and ventricular conduction delay. (Abstract). J Am Coll Cardiol 2000;35:901-2.
77. Toussaint JF, Ritter P, Lavergne T, et al. Biventricular resynchronization in endstage heart failure: an eight-months follow up by phase map radionuclide angiography. (Abstract). Pacing Clin Electrophysiol 1999;22:561.
78. Curry CW, Nelson GS, Wyman BT, et al. Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. Circulation 2000;101:e2.
79. Breithardt OA, Stellbrink C, Diem B, et al. Effect of chronic multisite pacing on left ventricular volumes in patients with congestive heart failure. (Abstract). Pacing Clin Electrophysiol 1999;22:131.
80. Stellbrink C, Breithardt OA, Diem B, et al. Acute effects of multisite pacing with different AV delays on diastolic and systolic functions in congestive heart failure. (Abstract). Pacing Clin Electrophysiol 1999;22:516.
81. Abraham WT, Fisher WG, Smith AL, et al. Cadiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
82. Sutton St John MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003;107:1985-90.
83. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure. A meta-analysis of randomised controlled trials. JAMA 2003;289:730-40.
84. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: comparison of medical therapy, pacing and defibrillation in chronic heart failure (COMPANION) trial. J Cardiac Failure 2000;6:276-85.
85. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
86. Young JB, Abraham WT, Smith A, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. The MIRACLE ICD trial. JAMA 2003;289:2685-94.
87. Rivero-Ayerza M, De Backer T, Vanderheyden M, et al. Indications for cardiac resynchronization therapy: should they be extended? Eur Heart J Suppl 2003;5(suppl 1):197-101.
88. Bader H, Garrigue S, Lafitte S, et al. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol 2004;43:248-56.
89. Cazeau S, Bordaghar P, Jauvert G, et al. Echocardiographic modelling of cardiac dyssynrony before and during multisite stimulation. Pacing Clin Electrophysiol 2003;26:137-43